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Abstract
Background: Synthetic activators of peroxisome proliferator-activated receptors (PPARs) stimulate cholesterol
removal from macrophages through PPAR-dependent up-regulation of liver × receptor a (LXRa) and subsequent
induction of cholesterol exporters such as ATP-binding cassette transporter A1 (ABCA1) and scavenger receptor
class B type 1 (SR-BI). The present study aimed to test the hypothesis that the hydroxylated derivative of linoleic
acid (LA), 13-HODE, which is a natural PPAR agonist, has similar effects in RAW264.7 macrophages.
Methods: RAW264.7 macrophages were treated without (control) or with LA or 13-HODE in the presence and
absence of PPARa or PPARg antagonists and determined protein levels of LXRa, ABCA1, ABCG1, SR-BI, PPARa and
PPARg and apolipoprotein A-I mediated lipid efflux.
Results: Treatment of RAW264.7 cells with 13-HODE increased PPAR-transactivation activity and protein
concentrations of LXRa, ABCA1, ABCG1 and SR-BI when compared to control treatment (P < 0.05). In addition, 13-
HODE enhanced cholesterol concentration in the medium but decreased cellular cholesterol concentration during
incubation of cells with the extracellular lipid acceptor apolipoprotein A-I (P < 0.05). Pre-treatment of cells with a
selective PPARa or PPARg antagonist completely abolished the effects of 13-HODE on cholesterol efflux and
protein levels of genes investigated. In contrast to 13-HODE, LA had no effect on either of these parameters
compared to control cells.
Conclusion: 13-HODE induces cholesterol efflux from macrophages via the PPAR-LXRa-ABCA1/SR-BI-pathway.
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Background
Although dietary consumption of oxidized fats (OF) is
known to cause some unfavourable effects (e.g., oxida-
tive stress, depletion of antioxidants; [1-3]), experiments
in laboratory animals and pigs consistently demon-
strated that administration of OF reduces lipid concen-
trations (triacylglycerols and cholesterol) in liver and
plasma (reviewed in [4]). Recent evidence suggests that
activation of the peroxisome proliferator-activated
receptor a (PPARa) pathway in the liver is largely
responsible for the lipid lowering action of OF [5-7].
PPARa is a ligand-activated transcription factor which
controls a comprehensive set of genes involved in most
aspects of lipid catabolism [8,9]. Thus, targeting PPARa
by the administration of pharmacological PPARa activa-
tors, e.g., fenofibrate, bezafibrate, gemfibrozil, is an effec-
tive approach for the treatment of hyperlipidemia [10].
Besides targeting lipid catabolism in the liver and reg-
ulating plasma lipid concentrations, synthetic PPARa
activators also directly influence vascular function in a
beneficial manner through negatively regulating the
expression of pro-inflammatory genes in vascular cells
such as endothelial cells, smooth muscle cells, and
macrophages and inducing genes involved in macro-
phage cholesterol homeostasis [11-13]. These direct
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are largely responsible for the observation that pharma-
cological PPARa activators cause an inhibition of ather-
osclerosis development [14-17]. Interestingly, in a recent
study it could be demonstrated that dietary administra-
tion of an OF also causes activation of PPARa in the
vasculature, inhibits expression of pro-inflammatory vas-
cular adhesion molecules, whose expression is negatively
regulated by PPARa, and inhibits atherosclerotic plaque
development in the low-density lipoprotein receptor
deficient mouse model of atherosclerosis [18]. These
findings suggest that OF exerts similar effects as phar-
macological PPARa agonists.
The components of OF which are supposed to be
responsible for PPARa activation are hydroxy and
hydroperoxy fatty acids, such as 13-hydroxy octadeca-
dienoic acid (13-HODE) or 13-hydroperoxy octadecadie-
noic acid (13-HPODE). These substances are formed
during oxidation of dietary lipids and absorbed from the
intestine following ingestion of these fats [19,20]. Using
different experimental approaches, such as ligand bind-
ing studies, transactivation assays and cell culture
experiments, it was shown that these oxidized fatty
acids are potent ligands and activators of PPARa
[21-24]. An animal experiment revealed that feeding a
diet supplemented with 13-HPODE reduces plasma tria-
cylglycerol concentrations indicating that oxidized fatty
acids are indeed the mediators of the lipid lowering
effects of OF [25]. Whether oxidized fatty acids are also
responsible for the observation that OF modulates the
expression of PPAR-dependent genes in the vasculature
[18], has not been studied yet. Therefore, the present
study aimed to test the hypothesis that the hydroxylated
derivative of linoleic acid, 13-HODE, induces genes
involved in macrophage cholesterol homeostasis, such as
liver × receptor a (LXRa), ATP-binding cassette trans-
porter A1 (ABCA1), ABCG1 and scavenger receptor
class B type 1 (SR-BI), and increases cholesterol removal
from macrophages in a PPAR-dependent manner.
Recent studies showed that synthetic activators of
PPARa stimulate cholesterol removal from macro-
phages, an important step in reverse cholesterol trans-
port, through PPAR-dependent up-regulation of LXRa
[26-28], which serves as an intracellular cholesterol sen-
sor and positively regulates expression of cholesterol
exporters such as ABCA1, ABCG1 and SR-BI [29].
Materials and methods
Cell culture and treatments
Mouse RAW264.7 cells, obtained from LGC Promo-
chem (Wesel, Germany), were grown in DMEM med-
ium (Gibco/Invitrogen, Karlsruhe, Germany)
supplemented with 10% fetal calf serum, 4 mmol/L L-
glutamine, 4.5 g/L glucose, 1 mmol/L sodium pyruvate,
1.5 g/L sodium bicarbonate and 0.5% gentamycin. Cells
were maintained at 37°C in a humidified atmosphere of
95% air and 5% CO2. RAW264.7 cells were plated in 6-
well plates at a density of 1 × 10
6/well for western blot
analysis and at a density of 8 × 10
5/well for cholesterol
analysis. After reaching 80% confluence, cells were trea-
ted with LA (≥96% pure) and 13-HODE (≥96% pure;
both from Sigma-Aldrich, Taufkirchen, Germany) at the
concentrations indicated for 24 h. Cells treated with
vehicle alone (ethanol) were used as controls. Incubation
media containing fatty acids were prepared by diluting
the fatty acid stock solutions (100 mmol/L LA and 2.5
mmol/L 13-HODE in ethanol) with DMEM medium to
100 μmol/L (LA) and 2.5 μmol/L (13-HODE), as also
described from others [30]. After addition of the fatty
acids to the medium, the medium was gently vortexed
at RT to ensure complete solubility of the added fatty
acids. No signs of precipitation could be observed. Due
to the presence of BSA in the medium, it is expected
that most of the added fatty acids was bound to albumin
which serves as the natural delivery molecule for free
fatty acids in plasma. The concentration of 13-HODE
used was based on the knowledge that this fatty acid
can be found in human blood in the low μmolar range
[31]. Incubation media of control cells contained the
same vehicle (ethanol) concentration of 0.1% (v/v). Spe-
cific precautions other than appropriate storage condi-
tions (-20°C, in the dark) were not taken to prevent
oxidation of LA and 13-HODE. 13-HODE has been
reported to be very stable against oxidation as evidenced
from air oxidation experiments with 13S-HODE which
were carried out by addition of amounts of iron ions
greatly surpassing the Fe
2+ concentration in biological
samples [32]. Even under extreme conditions, such as
elevated temperature (45-50°C) and enhanced reaction
time (2 weeks), 95% of the 13S-HODE was recovered
unchanged by GC-MS analysis [32]. For experiments
using PPAR inhibitors, cells were pre-treated with either
10 μmol/L of the PPARa selective antagonist GW6471
(Sigma-Aldrich) or 20 μmol/L of the PPARg selective
antagonist GW9662 (Sigma-Aldrich) 4 h before treat-
ment with fatty acids. All experiments were performed
between passages 5 and 8.
Western blot analysis
After treatment of cells as indicated above, cells were
lysed with RIPA lysis buffer (50 mmol/L Tris pH 7.5,
150 mmol/L NaCl, 1 mmol/L EDTA, 1% Triton X-100,
1% sodium deoxycholate, 0.1% SDS) containing protease
inhibitor cocktail (Sigma), and protein concentrations of
lysates determined by the BCA assay (VWR, Darmstadt,
Germany). Equal amounts of protein were electrophor-
esed by 7.5% SDS-PAGE for ABCA1 and ABCG1 and
10% SDS-PAGE for SR-BI and LXRa and transferred to
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Page 2 of 10a nitrocellulose membrane. The membranes were
blocked at 4°C in blocking solution (5% skim milk in
Tris buffered saline with Tween-20 [TBS-T]: 50 mmol/L
T r i s ,1 5 0m m o l / LN a C l ,p H7 . 5 ,0 . 2 %T w e e n - 2 0 ) ,a n d
then incubated with primary antibodies against ABCA1
(1:1,000, Novus Biologicals), ABCG1 (1:2000, Abcam),
b-Actin (1:1,000, Novus Biologicals), SR-B1 (1:1,000,
Novus Biologicals), LXRa (1:500, Affinity BioReagents)
for 2 h at room temperature or overnight at 4°C
depending on the antibody used. The membranes were
washed with TBS-T, and incubated with a horseradish
peroxidase conjugated secondary anti-mouse IgG anti-
body (1:10,000, Jackson Immuno Research) or anti-rab-
bit IgG antibody (1:10,000, Sigma-Aldrich) for 1.5 h at
room temperature. Afterwards blots were developed
using ECL Advance (GE Healthcare Europe, Freiburg,
Germany) for polyclonal antibodies and ECL Plus (GE
Healthcare Europe) for monoclonal antibodies. The sig-
nal intensities of specific bands were detected with Bio-
Imaging system (Syngene, Cambridge, UK) and quanti-
fied using Syngene GeneTools software (Nonlinear
Dynamics, USA).
Analysis of cholesterol content in medium and cells
After pre-treatment with or without PPAR antagonists
and treatment of macrophage cells with or without fatty
acids as indicated above, cells were incubated again with
the antagonists for 4 h and afterwards with or without
the corresponding fatty acids in the presence or absence
of apolipoprotein A-I (apoA-I) (30 μg/mL) for 24 h.
Afterwards, medium was collected and removed from
detached cells by a centrifugation step, and the cell
monolayer washed twice with PBS. Cellular lipids were
extracted with a mixture of hexane and isopropanol (3:2,
v/v) and lipids in the medium were extracted with a mix-
ture of chloroform and methanol (2:1, v/v). Lipid extracts
were dried under a stream of nitrogen and total choles-
terol concentrations were determined using an enzymatic
assay from Biocon (Vöhl-Marienhagen, Germany). Cho-
lesterol concentrations were related to cellular protein
content as determined by the BCA protein assay kit.
Transient transfection and dual luciferase assay
RAW264.7 cells were plated in 24-well plates at a density
of 5 × 10
5/well. After reaching 70% confluence, cells were
transiently transfected with 500 ng of a 3 × ACO-PPRE
reporter vector (containing three copies of consensus
PPRE from the ACO promoter in front of a luciferase
reporter gene; a generous gift from Dr. Sander Kersten,
Nutrigenomics Consortium, Top Institue (TI) Food and
Nutrition, Wageningen, Netherlands) using FuGENE 6
transfection reagent (Roche Diagnostics, Mannheim,
Germany) according to the manufacturer’sp r o t o c o l .
Cells were also co-transfected with 50 ng of pGL4.74
Renilla luciferase (encoding the renilla luciferase reporter
gene; Promega, Mannheim, Germany), which was used as
an internal control reporter vector to normalize for dif-
ferences in transfection efficiency. Following transfection,
cells were treated with either WY-14,643 (as positive
control), LA, 13-HODE or vehicle only (DMSO and etha-
nol) at the concentrations indicated for 24 h. Afterwards,
cells were washed with PBS and lysed with passive lysis
buffer (Promega). Luciferase activities were determined
with the Firefly and Renilla Luciferase Assays (PJK, Klein-
blittersdorf, Germany) according to the manufacturer’s
instructions using a Mithras LB940 luminometer (Bert-
hold Technologies, Bad Wildbad, Germany) as described
recently in more detail [33].
Statistical analysis
Data were subjected to either Student’s t-test or one-way
ANOVA using the Minitab Statistical Software Rel. 13.0
(Minitab, State College, PA, USA). For statistically signifi-
cant F values, individual means of the treatment groups
were compared by Fisher’sm u l t i p l er a n g et e s t .M e a n s
were considered significantly different for P < 0.05.
Results
Effects of 13-HODE and LA on PPAR transactivation
activity and PPAR protein levels in RAW264.7
macrophages
To study the effect of 13-HODE and LA on the activa-
tion of the PPAR signalling pathway in macrophages,
RAW264.7 were transiently transfected with a reporter
plasmid containing 3 copies of the consensus PPRE in
front of a luciferase reporter and studied the stimulation
of the reporter activity by 13-HODE and LA as well as
by the synthetic PPARa agonist WY-14,643. Treatment
with WY-14,643 as a positive control increased PPAR-
responsive reporter activity by about 90% compared to
treatment with vehicle alone (P < 0.05; Figure 1A).
Treatment with 13-HODE dose-dependently increased
the PPAR-responsive reporter activity compared to
treatment with vehicle alone (P < 0.05; Figure 1A);
incubating RAW264.7 cells with 1.0 and 2.5 μmol/L of
13-HODE increased the PPAR-responsive reporter
activity by about 28 and 50%, respectively, compared to
vehicle control. Incubation of macrophages with
increasing concentrations of LA had no effect on the
PPAR-responsive reporter activity when compared to
macrophages treated with vehicle alone (Figure 1A);
there was only a numerical, but not significant increase
in the PPAR-responsive reporter activity at the highest
concentration of LA (100 μmol/L) when compared to
vehicle control. Protein concentrations of PPARa and
PPARg did not differ between control macrophages and
macrophages treated with either 2.5 μmol/L 13-HODE
or 100 μmol/L LA (Figure 1B).
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Figure 1 Effects of 13-HODE, LA and WY-14,643 on PPAR/PPRE transactivation activity and PPAR protein levels in RAW264.6
macrophages. A, RAW264.7 cells were transiently transfected with 3 × ACO-PPRE reporter vector. After transfection, cells were treated or not
with 0.1-2.5 μmol/L 13-HODE, 1-100 μmol/L LA and 50 μmol/L WY-14,643 for 24 h. Afterwards, cells were lysed, and luciferase activities of the
ACO-PPRE firefly luciferase vector and a co-transfected renilla luciferase vector determined by a dual luciferase assay. Bars represent means ± SD
from four independent experiments (n = 4). Data are expressed as percentage of relative luciferase activity of vehicle control cells. Results from
statistical analysis are indicated: Significant effects are denoted with an asterisk (P < 0.05). B, RAW264.7 cells were treated with 2.5 μmol/L 13-
HODE, 100 μmol/L LA or vehicle (ethanol) for 24 h. Afterwards, cells were lysed and subsequently processed for western blotting as described in
the materials and methods section. Representative immunoblots specific for PPARa, PPARg, and b-actin which was used for normalization are
shown. Bars represent data from densitometric analysis and are means ± SD from three independent experiments (n = 3). Data are expressed as
percentage of protein concentration of vehicle control cells.
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Page 4 of 10Effects of 13-HODE and LA in the presence and absence
of PPARa and PPARg selective antagonists on relative
protein concentrations of ABCA1, ABCG1, SR-BI and LXRa
in RAW264.7 macrophages
To explore the involvement of PPARa and PPARg in the
action of 13-HODE on proteins regulating cholesterol
homeostasis, cells were pre-treated without or with selec-
tive PPARa and PPARg antagonists prior to treatment
with fatty acids. In the absence of an antagonist, 2.5 μmol/
L of 13-HODE increased protein levels of ABCA1,
ABCG1, SR-BI and LXRa in RAW264.7 macrophages (P <
0.05; Figure 2A and 2B), whereas 100 μmol/L of LA had
no effect (Figure 3A and 3B). When cells were pre-treated
with either the PPARa antagonist GW6471 or the PPARg
antagonist GW9662 the effect of 13-HODE on the con-
centrations of these proteins was completely abolished
(Figure 2A and 2B). In cells treated with LA, the pre-treat-
ment with GW6471 caused a 15-25% decrease in the pro-
tein levels of ABCA1 and SR-BI (P < 0.05; Figure 2A and
2B), whereas protein levels of ABCG1 and LXRa remained
unaffected. Pre-treatment with GW9662 did not alter the
effect of LA on protein levels of ABCA1, ABCG1, SR-BI
and LXRa in comparison to treatment without PPARa or
PPARg antagonist (Figure 2A and 2B).
Effects of 13-HODE and LA on cholesterol concentrations
in macrophages in the presence and absence of apoA-I
and PPARa and PPARg antagonists
To investigate whether the 13-HODE-induced alterations
of the expression of proteins involved in cholesterol home-
ostasis had an effect on macrophage cholesterol content,
we determined the cholesterol concentrations of cells and
medium after treatment with 13-HODE and LA, both in
the presence and absence of the extracellular lipid acceptor
apo-AI. In the absence of apoA-I, cholesterol concentra-
tions in cells and medium did not differ between control
macrophages and macrophages treated with either LA or
13-HODE (Figure 3A and 3B). In the presence of apoA-I,
treatment with 13-HODE decreased cellular cholesterol
concentration by approximately 15% (P < 0.05; Figure 3A
and 3B) and increased cholesterol concentration in med-
ium by approximately 25% when compared to treatment
with vehicle alone (P < 0.05; Figure 3A and 3B). In contrast,
treatment with LA in the presence of apoA-I had no effect
on cholesterol concentrations in cells and medium when
compared to control treatment (Figure 3A and 3B). When
cells were pre-treated with either the PPARa antagonist
GW6471 or the PPARg antagonist GW9662 the effect of
13-HODE on cellular and medium cholesterol concentra-
tion was completely abolished (Figure 3A and 3B).
Discussion
Pharmacological PPAR ligands have been demonstrated
to induce cholesterol removal from macrophages and to
prevent macrophage foam cell formation through altera-
tions in the expression of genes critically involved in
macrophage cholesterol homeostasis [26-28]. Feeding
OF was repeatedly shown to cause PPARa activation in
tissues of different species [4]. This effect has been
attributed to characteristic substances of OF such as
hydroxylated fatty acids,e . g .1 3 - H O D E ,w h i c ha r e
known ligands of PPARs [34,35]. The present study
shows that 13-HODE moderately, but significantly low-
ers the cellular cholesterol content of macrophages
while increasing the cholesterol content in the medium
when apo-AI, the main apo of high density lipoprotein
(HDL) particles, is present in the culture medium as an
extracellular cholesterol acceptor. The export of choles-
terol to acceptors such as apoA-I or HDL is an impor-
tant part of the reverse cholesterol transport responsible
for redistribution of cholesterol from peripheral tissues
to the liver. Recent studies in RAW264.7 macrophages
provided evidence that apoA-I is internalized by endocy-
tosis into the macrophage where it acquires free choles-
terol from intracellular pools before it is resecreted by
exocytosis (novel model of cholesterol efflux called ret-
roendocytosis), and that apoA-I internalization is
required for transporter-mediated cholesterol efflux [36].
In the absence of apoA-I, no effect of 13-HODE on
macrophage cholesterol content and cholesterol content
in the incubation medium was observed. Thus, our find-
ings indicate that 13-HODE stimulates specifically
apoA-I-dependent cholesterol efflux in macrophages, an
effect that is also known from synthetic PPAR ligands
[26-28]. Interestingly, a previous study has shown that
dietary oxidized fatty acids enhance intestinal cell apoA-
I production via a PPAR-dependent process [37].
Although it has to be considered that plasma HDL
levels are also determined by hepatic apoA-I synthesis
and nascent HDL particle secretion, these previous find-
ings together with our findings herein may be indicative
of the ability of oxidized fatty acids to stimulate reverse
cholesterol transport. Interestingly, evidence from feed-
ing studies indeed shows that treatment of rats and gui-
nea pigs with oxidized fat increases HDL cholesterol
concentrations in plasma [3,38]. In pigs, however, which
are better model objects for humans, no effect of oxi-
dized fat on HDL cholesterol concentrations apoA-I
production was found [39]. Epidemiological associations
between oxidized fat intake and plasma HDL cholesterol
in humans have not been established. This is probably
explained by the fact that it is difficult to estimate the
intake of oxidized fat.
On the molecular level, reduction of macrophage cho-
lesterol accumulation and stimulation of cholesterol
efflux from macrophages to extracellular lipid acceptors
by PPAR agonists has been explained by an up-regula-
tion of LXRa and subsequent induction of macrophage
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Figure 2 Effects of 13-HODE and LA in the presence and absence of PPARa and PPARg selective antagonists on molecular markers of
cholesterol homeostasis in RAW264.7 macrophages. RAW264.7 cells were pre-treated without or with the PPARa selective antagonist
GW6471 or the PPARg selective antagonist GW9662 and subsequently treated without (vehicle control) or with 2.5 μmol/L 13-HODE or 100
μmol/L LA for 24 h. Afterwards, cells were lysed and subsequently processed for western blotting as described in the materials and methods
section. A, Representative immunoblots specific for ABCA1, ABCG1, SR-BI, LXRa, and b-actin which was used for normalization are shown. B, Bars
represent data from densitometric analysis and are means ± SD from three independent experiments (n = 3). Data are expressed as percentage
of protein concentration of vehicle control cells. Results from statistical analysis are indicated: Significant effects are denoted with superscript
letters. Bars marked without a common superscript letter significantly differ (P < 0.05).
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Figure 3 Effects of 13-HODE and LA on cholesterol concentrations in cells and medium of macrophages in macrophages in the
presence and absence of apoA-I and PPARa and PPARg antagonists. After pre-treatment without or with PPAR antagonists for 4 h and
treatment of RAW264.7 macrophage cells without (vehicle control) or with 2.5 μmol/L 13-HODE or 100 μmol/L LA for 20 h, cells were incubated
again without or with the antagonists for 4 h and afterwards without or with the corresponding fatty acids in the presence or absence of
apolipoprotein A-I (apoA-I) (30 μg/mL) for 24 h. Afterwards, medium was collected, and cells were washed with PBS. Total lipids were extracted
from medium and cells and concentrations of cholesterol determined as described in the materials and methods section. A, Cellular and B,
medium cholesterol concentrations were related to cellular protein content. Bars represent means ± SD from four independent experiments (n =
4). Data are expressed as percentage of cholesterol concentration in cells and medium of control cells. Results from statistical analysis are
indicated: Significant effects are denoted with an asterisk (P < 0.05).
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Page 7 of 10cholesterol exporters [26-28], like ABCA1 and ABCG1,
which are direct LXRa target genes. Induction of SR-BI,
which facilitates a bidirectional flux of free cholesterol
between cells and lipoproteins, in response to PPAR
agonists [40,41] is also considered to contribute to the
increased macrophage cholesterol efflux and reverse
cholesterol transport. Like ABCA1 and ABCG1, SR-BI
promoter activity and protein levels are also positively
regulated by LXRa through a functional LXR response
element in its gene promoter [42]. Up-regulation of
LXRa in response to PPAR agonists is attributed to the
fact that LXRa is regulated by PPARs through a func-
tional PPRE in the LXRa gene promoter [28,43]. Given
that the blockade of PPARa or PPARg by the use of
selective PPARa or PPARg antagonists in RAW264.7
cells resulted in a complete loss of the stimulatory effect
of 13-HODE on LXRa, ABCA1, ABCG1 and SR-BI and
cholesterol efflux, we suggest that 13-HODE exerted its
effect on macrophage cholesterol homeostasis in a
PPAR ligand-like manner. Conversely, the lack of effect
of LA on cellular and medium cholesterol content and
expression of LXRa, ABCA1, ABCG1 and SR-BI is
probably explained by its failure to cause PPAR activa-
tion in RAW264.7 macrophages. The failure of LA to
cause PPAR activation is likely due to the lower binding
affinity of PPARs for unoxidized fatty acids compared
with oxidized fatty acids like 13-HODE [44]. In line
with this assumption are observations from several inde-
pendent groups showing that LA does not induce PPAR
target genes in both murine RAW264.7 [45,46] and
human THP-1 macrophages [47].
As regards our observations with LA, it has to be
mentioned that some studies reported that LA even
decreases protein levels of ABCA1 and/or ABCG1 in
either J774 macrophages or RAW264.7 macrophages
[48-51]. Although it is difficult to provide a definite rea-
son for this discrepancy, it is well known from the lit-
erature that cell culture studies dealing with fatty acids,
in particular with LA, provided very controversial results
[52]. Important reasons that may be responsible for
these discrepancies could be differences in the passage
number of cells or differences in the treatment regime,
such as time of exposure and fatty acid concentration.
Regarding the latter point, it is worth mentioning that
in two of the abovementioned studies [48,49] the con-
centration of LA in the medium was higher than in the
present study.
Recent studies demonstrated that PPAR activation also
stimulates postlysosomal mobilization of cholesterol by
induction of Niemann-Pick C (NPC)-1 and NPC-2 [53].
Both proteins control intracellular trafficking of choles-
terol from the late endosomal compartment and lyso-
some, respectively, to the plasma membrane [54]. It has
been suggested [53] that up-regulation of NPC-1 and -2
in response to PPAR agonists results in an enhanced
availability of cholesterol at the cell membrane, and,
thereby, contributes to increases in macrophage choles-
terol efflux to extracellular acceptors and reverse choles-
terol. For technical reasons we were not capable to
determine protein expression of NPC-1 and NPC-2 in
RAW264.7 macrophages. However, due to the observed
similarities in the action of 13-HODE and synthetic
PPAR ligands on macrophage cholesterol homeostasis
we postulate that 13-HODE might also stimulate postly-
sosomal cholesterol mobilization. This has to be clarified
in future studies. However, the regulation of cholesterol
homeostasis in macrophages is complex and there are
several other proteins important for maintenance of
cholesterol homeostasis, including low density-lipopro-
tein (LDL) receptor, acyl-CoA cholesterol:acyltransfer-
ase, hydroxymethyl-glutaryl-CoA reductase, sterol
regulatory element-binding proteins, steroidogenic acute
regulatory (STAR)-related lipid transfer domain pro-
teins, e.g. Star D4, and caveolin-1. Caveolin-1 for
instance has been recently reported to be up-regulated
by PPARa and PPARg agonists [55]. It is therefore not
unlikely that 13-HODE exerts its effect on macrophage
cholesterol homeostasis also by altering the expression
of one or more of these proteins. Thus, future studies
applying transcriptomics or proteomics may be useful to
get a more comprehensive insight into the mode of
action of 13-HODE.
Oxidized fatty acids such as 13-HODE were also
shown to activate the PPARg isotype [34,35,56].
Although PPARg is a less likely candidate for the media-
tion of the lipid lowering actions of OF, because PPARg
is poorly expressed in tissues with high rates of fatty
acid catabolism like liver and skeletal muscle, it may be
a putative mediator of the effect of 13-HODE on
RAW264.7 macrophage cholesterol homeostasis. PPARg
is abundantly expressed in macrophage cell lines includ-
ing RAW264.7 cells, as shown herein by western blot-
ting, as well as primary macrophages [35]. In addition,
synthetic PPARg agonists were reported to stimulate
macrophage cholesterol efflux by the same mechanisms
as PPARa agonists, namely through activating the
PPAR-LXR-pathway [12]. From our PPAR/PPRE-trans-
activation experiments, we cannot distinguish whether
the activation of the reporter was due to activation of
either PPARa or PPARg because the PPRE from the
mouse ACO promoter contained in the reporter plasmid
used is known to be bound by both, PPARa and PPARg
[57]. Collectively, we suggest that the effects observed
with 13-HODE on macrophage cholesterol homeostasis
may be mediated by activating either PPARa,P P A R g or
both of them.
Independent from the stimulatory effect of 13-HODE
on proteins involved in macrophage cholesterol efflux, it
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untoward effects have been reported in cell culture
experiments, such as up-regulation of scavenger recep-
tor CD36 which mediates the uptake of oxidized LDL
[56]. Therefore, future studies using appropriate animal
models of atherosclerosis, such as low density-lipopro-
tein-deficient or apolipoprotein E-deficient mice, have to
clarify whether or not diets containing high levels of 13-
HODE promote atherosclerosis development. Evidence
from epidemiological studies concerning intake of oxi-
dized fatty acids and cardiovascular disease risk is miss-
ing due to the lack of appropriate studies correlating the
intake of oxidized fats with the incidence of cardiovas-
cular diseases. Correlating the consumption of fried
food with cardiovascular disease risk does not contribute
to the clarification of this question because the lipid
fraction of fried food contains not only oxidized fatty
acids, but also large amounts of saturated fatty acids
and trans-fatty acids which themselves influence cardio-
vascular disease risk.
Conclusions
The present study shows that 13-HODE reduces choles-
terol content in murine RAW264.7 macrophages and
increases cholesterol content in the incubation medium
probably by stimulating apoA-I-dependent cholesterol
efflux in a PPAR-dependent manner. The 13-HODE-
induced increase in cholesterol efflux from macrophages
is likely due to PPAR-dependent up-regulation of LXRa
and cholesterol transporters (ABCA1, ABCG1, SR-BI)
which operate on cholesterol export to extracellular
acceptors such as apoA-I/HDL. Because extensive accu-
mulation of cholesterol by macrophages in the arterial
wall leads to atherosclerosis, the present findings in
macrophages suggest that the recently observed anti-
atherogenic effects of OF [18] might be, at least in part,
due to the inhibition of macrophage cholesterol accu-
mulation and stimulation of reverse cholesterol trans-
port caused by oxidized fatty acids such as 13-HODE.
Future studies in human monocyte/macrophage cell
lines, such as THP-1 cells, or human primary macro-
phages have to show whether the effects observed in
murine macrophages also occur in human macrophages.
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